Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry

Major investors and tech giants are positioning around AI-driven biology and longevity, making programmable biology an emerging investment theme. The article identifies NVIDIA as the primary infrastructure play—its BioNeMo platform and a $1 billion co-innovation lab with Eli Lilly—and Eli Lilly as the blue-chip applied-biology exposure. Billionaire-backed startups (e.g., NewLimit, Altos Labs) and reported private funding bolster the narrative, though some figures are unverified. NVIDIA reported very strong Q1 FY2027 results, while Eli Lilly raised guidance after robust Q1 2026 results. The piece views NVDA and LLY as the most practical public-market vehicles for this theme but warns both trade at rich multiples, advising investors to size positions carefully.